Denmark's TopoTarget AS and USA-based CuraGen say they have initiated a Phase I clinical trial of PXD101 as a treatment for patients with solid tumors. The drug, which is a small-molecule histone deacetylase inhibitor, is also under assessment in a series of Phase II trials as a therapy for blood cancers (Marketletter August 9).
The Phase I solid-tumor study will be an open-label, multicenter assessment of the compound, which is designed to establish its maximum tolerated dose, safety and tolerability.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze